FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other EventsItem 8.01 Other Events
On December 29, 2017, Fibrocell Science Inc., posted an updated Corporate Presentation on its website www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Corporate Presentation dated December 29, 2017 |
EXHIBITINDEX
|
Exhibit No. |
Description |
|
Corporate Presentation dated December 29, 2017
|
Fibrocell Science, Inc. ExhibitEX-99..1 2 a12292017finalfcsccorpor.htm EXHIBIT 99..1 a12292017finalfcsccorpor Corporate Presentation
December 29,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
